152 related articles for article (PubMed ID: 32727487)
1. Location matters: highly divergent protein levels in samples from different CNS compartments in a clinical trial of rituximab for progressive MS.
Bergman J; Svenningsson A; Liv P; Bergenheim T; Burman J
Fluids Barriers CNS; 2020 Jul; 17(1):49. PubMed ID: 32727487
[TBL] [Abstract][Full Text] [Related]
2. Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement.
Bhargava P; Wicken C; Smith MD; Strowd RE; Cortese I; Reich DS; Calabresi PA; Mowry EM
Mult Scler Relat Disord; 2019 May; 30():136-140. PubMed ID: 30771580
[TBL] [Abstract][Full Text] [Related]
3. CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage.
Romme Christensen J; Komori M; von Essen MR; Ratzer R; Börnsen L; Bielekova B; Sellebjerg F
Mult Scler; 2019 Jun; 25(7):937-946. PubMed ID: 29775134
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid:serum glucose ratio in the ventricular and lumbar compartments: implications for clinical practice.
Hegen H; Walde J; Auer M; Deisenhammer F
Eur J Neurol; 2018 Feb; 25(2):373-379. PubMed ID: 29115000
[TBL] [Abstract][Full Text] [Related]
5. Intrathecal treatment trial of rituximab in progressive MS: An open-label phase 1b study.
Bergman J; Burman J; Gilthorpe JD; Zetterberg H; Jiltsova E; Bergenheim T; Svenningsson A
Neurology; 2018 Nov; 91(20):e1893-e1901. PubMed ID: 30305449
[TBL] [Abstract][Full Text] [Related]
6. Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial.
Romme Christensen J; Ratzer R; Börnsen L; Lyksborg M; Garde E; Dyrby TB; Siebner HR; Sorensen PS; Sellebjerg F
Neurology; 2014 Apr; 82(17):1499-507. PubMed ID: 24682973
[TBL] [Abstract][Full Text] [Related]
7. Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial.
de Flon P; Laurell K; Sundström P; Blennow K; Söderström L; Zetterberg H; Gunnarsson M; Svenningsson A
Acta Neurol Scand; 2019 May; 139(5):462-468. PubMed ID: 30740668
[TBL] [Abstract][Full Text] [Related]
8. The effects of intrathecal rituximab on biomarkers in multiple sclerosis.
Topping J; Dobson R; Lapin S; Maslyanskiy A; Kropshofer H; Leppert D; Giovannoni G; Evdoshenko E
Mult Scler Relat Disord; 2016 Mar; 6():49-53. PubMed ID: 27063622
[TBL] [Abstract][Full Text] [Related]
9. Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.
Öhrfelt A; Axelsson M; Malmeström C; Novakova L; Heslegrave A; Blennow K; Lycke J; Zetterberg H
Mult Scler; 2016 Oct; 22(12):1587-1595. PubMed ID: 26754805
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotein dynamics in the cerebrospinal fluid: intraindividual concomitant ventricular and lumbar measurements.
Brandner S; Thaler C; Lewczuk P; Lelental N; Buchfelder M; Kleindienst A
Eur Neurol; 2013; 70(3-4):189-94. PubMed ID: 23969528
[TBL] [Abstract][Full Text] [Related]
11. Progressive multiple sclerosis cerebrospinal fluid induces inflammatory demyelination, axonal loss, and astrogliosis in mice.
Cristofanilli M; Rosenthal H; Cymring B; Gratch D; Pagano B; Xie B; Sadiq SA
Exp Neurol; 2014 Nov; 261():620-32. PubMed ID: 25111532
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
Axelsson M; Malmeström C; Gunnarsson M; Zetterberg H; Sundström P; Lycke J; Svenningsson A
Mult Scler; 2014 Jan; 20(1):43-50. PubMed ID: 23702432
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Cerebrospinal Fluid Extracellular Vesicles by Proximity Extension Assay: A Comparative Study of Four Isolation Kits.
Sjoqvist S; Otake K; Hirozane Y
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33321992
[TBL] [Abstract][Full Text] [Related]
14. Proteomics of brain extracellular fluid (ECF) and cerebrospinal fluid (CSF).
Maurer MH
Mass Spectrom Rev; 2010; 29(1):17-28. PubMed ID: 19116946
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid concentrations of ghrelin in patients with multiple sclerosis.
Unger MM; Oertel WH; Tackenberg B
Neuro Endocrinol Lett; 2013; 34(1):14-7. PubMed ID: 23524619
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel.
Stilund M; Gjelstrup MC; Petersen T; Møller HJ; Rasmussen PV; Christensen T
PLoS One; 2015; 10(4):e0119681. PubMed ID: 25860354
[TBL] [Abstract][Full Text] [Related]
17. A comparison between ventricular and lumbar cerebrospinal fluid cytology in adult patients with leptomeningeal metastases.
Chamberlain MC; Kormanik PA; Glantz MJ
Neuro Oncol; 2001 Jan; 3(1):42-5. PubMed ID: 11305416
[TBL] [Abstract][Full Text] [Related]
18. Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers.
Ottervald J; Franzén B; Nilsson K; Andersson LI; Khademi M; Eriksson B; Kjellström S; Marko-Varga G; Végvári A; Harris RA; Laurell T; Miliotis T; Matusevicius D; Salter H; Ferm M; Olsson T
J Proteomics; 2010 Apr; 73(6):1117-32. PubMed ID: 20093204
[TBL] [Abstract][Full Text] [Related]
19. Different Metabolomic and Proteomic Profiles of Cerebrospinal Fluid in Ventricular and Lumbar Compartments in Relation to Leptomeningeal Metastases.
Kwon JW; Im JH; Lee KY; Yoo BC; Lee JH; Kim KH; Kim JH; Shin SH; Yoo H; Gwak HS
Metabolites; 2022 Jan; 12(1):. PubMed ID: 35050202
[TBL] [Abstract][Full Text] [Related]
20. Butyrylcholinesterase in lumbar and ventricular cerebrospinal fluid.
Kluge WH; Kluge HH; Hochstetter A; Vollandt R; Bauer HI; Venbrocks R
Acta Neurol Scand; 2001 Jul; 104(1):17-23. PubMed ID: 11442438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
